10.1002/anie.201810548
Angewandte Chemie International Edition
COMMUNICATION
[3]
[4]
J. G. Tillet, Sulfinamides. In The Chemistry of Sulphinic Acids, Esters
and their Derivatives; S. Patai, Ed.; Wiley: Chichester, 1990; pp 603–
622.
C. Martinez-Lamenca, J. E. Leenaerts, A. A. Trabanco, D. Oehlrich, J.
Org. Chem. 2017, 82, 9898–9904; (j) U. Lücking, F. Izzo, M. Schafer, R.
Stockman, Chem. Eur. J. 2017, 23, 15189–15193; (k) T. Q. Davies, A.
Hall, M. C. Willis, Angew. Chem. Int. Ed. 2017, 56, 14937–14941;
Angew. Chem. 2017, 129, 15133–15137; (l) M. Wright, C. Martinez-
Lamenca, J. E. Leenaerts, P. E. Brennan, A. A. Trabanco, D. Oehlrich,
J. Org. Chem. 2018, 83, 9510–9516; (m) B. Gao, S. Li, P. Wu, J. E.
Moses, K. B. Sharpless, Angew. Chem. Int. Ed. 2018, 57, 1939–1943;
Angew. Chem. 2018, 130, 1957–1961.
(a) J. A. Ellman, T. D. Owens, T. P. Tang, Acc. Chem. Res. 2002, 35,
984–995; (b) M. T. Robak, M. A. Herbage, J. A. Ellman, Chem. Rev.
2010, 110, 3600–3740.
[5]
[6]
S. Otocka, M. Kwiatkowska, L. Madalińska, P. Kiełbasiński, Chem. Rev.
2017, 117, 4147–4181.
For examples of sulfonamide-containing compounds employed in
industrial settings, see: (a) J. J. Talley, D. L. Brown, J. S. Carter, M. J.
Graneto, C. M. Koboldt, J. L. Masferrer, W. E. Perkins, R. S. Rogers, A.
F. Shaffer, Y. Y. Zhang, B. S. Zweifel, K. Seibert, J. Med. Chem. 2000,
43, 775–777; (b) D. Guianvarc'h, M. Duca, C. Boukarim, L. Kraus-
Berthier, S. Léonce, A. Pierre, B. Pfeiffer, P. Renard, P. B. Arimondo, C.
Monneret, D. Dauzonne, J. Med. Chem. 2004, 47, 2365–2374; (c) H.
Fan, G. Xu, Y. Chen, Z. Jiang, S. Zhang, Y. Yang, R. Ji, Eur. J. Med.
Chem. 2007, 42, 1137–1143; (d) M. Mojzych, Z. Karczmarzyk, W.
Wysocki, M. Ceruso, C. T. Supuran, V. Krystof, Z. Urbanczyk-
Lipkowska, P. Kalicki, Bioorg. Med. Chem. 2015, 23, 1421–1429.
Both sulfinamides and sulfonamides are regarded as bioisosteres of
amides in peptidomimetics. For guiding references, see: (a) W. J.
Moree, G. A. van der Marel, R. J. Liskamp, J. Org. Chem. 1995, 60,
5157–5169; (b) A. K. Ghosh, L. M. Swanson, H. Cho, S. Leshchenko, K.
A. Hussain, S. Kay, D. E. Walters, Y. Koh, H. Mitsuya, J. Med. Chem.
2005, 48, 3576–3585; (c) for a general review, see: N. A. Meanwell, J.
Med. Chem. 2011, 54, 2559–2591.
[16] For various structural modifications and applications of sulfonimidamide
derivatives, see: (a) C. Worch, C. Bolm, Synthesis 2007, 1355–1358;
(b) C. Worch, C. Bolm, Synthesis 2008, 739–742; (d) C. Worch, C.
Bolm, Synlett 2009, 2425–2428; (e) M. Steurer, C. Bolm, J. Org. Chem.
2010, 75, 3301–3310; (f) F. W. Patureau, C. Worch, M. A. Siegler, A. L.
Spek, C. Bolm, J. N. H. Reek, Adv. Synth. Catal. 2012, 354, 59–64.
[17] Until now, only reactions with N-aryl sulfinamides have been studied. If
other derivatives can be applied needs to be investigated and will be
part of future work.
[18] This assumption was substantiated by the degradation of the NH-
analog of 8ac in the presence of 1a or 2a, which led to 3ac in
significant amounts under the standard catalysis conditions depicted in
Scheme 5. For details, see the Supporting Information.
[7]
[19] The catalysis is not inhibited by the presence of 2 equiv of TEMPO, as
shown by the coupling of 1a and 2a, which gave 3aa in 67% yield under
the standard catalysis conditions depicted in Scheme 2. For details, see
the Supporting Information.
[8]
[9]
(a) C. He, C. Chen, J. Cheng, C. Liu, W. Liu, Q. Li, A. Lei, Angew.
Chem. Int. Ed. 2008, 47, 6414–6417; Angew. Chem. 2008, 120, 6514–
6517; (b) X. Tang, L. Huang, C. Qi, X. Wu, W. Wu, H. Jiang, Chem.
Commun. 2013, 49, 6102–6104; (c) H. Zhu, Y. Shen, Q. Deng, T. Tu,
Chem. Commun. 2015, 51, 16573–16576; For a recent example: (d) Q.
Dai, J. Zhang, Adv. Synth. Catal. 2018, 360, 1123 –1127.
For review on applying of O-benzoylhydroxylamines in the construction
of the C-N bond, see: X. Dong, Q. Liu, Y. Dong, H. Liu, Chem. Eur. J.
2017, 23, 2481–2511.
[10] See the Supporting Information for details.
[11] (a) D. Niu, S. L. Buchwald, J. Am. Chem. Soc. 2015, 137, 9716–9721;
(b) Z. Zhou, Z. Ma, N. E. Behnke, H. Gao, L. Kürti, J. Am. Chem. Soc.
2017, 139, 115–118.
[12] For recent summaries, see: (a) P. K. Chinthakindi, T. Naicker, N. Thota,
T. Govender, H. G. Kruger, P. I. Arvidsson, Angew. Chem. Int. Ed.
2017, 56, 4100–4109; Angew. Chem. 2017, 129, 4160–4170; (b) G. C.
Nandi, P. I. Arvidsson, Adv. Synth. Catal. 2018, 360, 2976–3001.
[13] (a) F. Sehgelmeble, J. Janson, C. Ray, S. Rosqvist, S. Gustavsson, L. I.
Nilsson, A. Minidis, J. Holenz, D. Rotticci, J. Lundkvist, P. I. Arvidsson,
ChemMedChem 2012, 7, 396–399; for related aspects, see: (b) S. R.
Borhade, R. Svensson, P. Brandt, P. Artursson, P. I. Arvidsson, A.
Sandström, ChemMedChem 2015, 10, 455–460.
[14] (a) R. Anand, J. M. Apgar, T. Biftu, P. Chen, L. Chu, V. J. Colandrea, G.
Dong, J. F. Dropinski, D. Feng, J. D. Hicks, Vol. WO2012116145 Merck,
Sharp and Dohme Corp., 2012; (b) W. Guba, W. Haap, A. Kuglstatter,
J.-U. Peters, U. Obst Sander, C. Schnider, R. Wermuth, T. Woltering,
Vol. WO2015091595A1, F. Hoffmann-La Roche AG, 2015; for
a
dermatological application, see: (c) A.-D. Steinkamp, L. Schmitt, X.
Chen, K. Fietkau, R. Heise, J. Baron, C. Bolm, Skin Pharm. Physiol.
2016, 29, 281–290.
[15] (a) E. Levchenko, A. Kirsanov, Zh. Obshch. Khim. 1960, 30, 1553–
1561; (b) C. Johnson, E. Jonnson, C. Bacon, J. Org. Chem. 1979, 44,
2055–2061; (c) O. García Mancheño, C. Bolm, Beilstein J. Org. Chem.
2007, 3, 25; (d) C. Worch, I. Atodiresei, G. Raabe, C. Bolm, Chem. Eur.
J. 2010, 16, 677–683; (e) M. Funes Maldonado, F. Sehgelmeble, F.
Bjarnemark, M. Svensson, J. Åhman, P. I. Arvidsson, Tetrahedron 2012,
68, 7456–7462; (f) S. R. K. Battula, G. V. Subbareddy, I. E.
Chakravarthy, Tetrahedron Lett. 2014, 55, 517–520; (g) Y. Chen, J.
Gibson, RSC Adv. 2015, 5, 4171–4174; (h) J. Wen, H. Cheng, S. Dong,
C. Bolm, Chem. Eur. J. 2016, 22, 5547–5550; (i) C. S. Richards-Taylor,
This article is protected by copyright. All rights reserved.